My Fund

Loading your portfolio…

Checking your account and saved picks.

Choose a startup

Explore all 1424 companies in this selection. Research each company before making your pick.

Includes historical VC holdings. A listing does not confirm current ownership or startup stage.

VC tracking →

Showing 1–1 of 1 startup

Third Arc Bio

Limited coverage

Bio + Health

RiseFinder summary

Third Arc Bio develops antibody technology for oncology and autoimmune conditions.

Andreessen Horowitz
thirdarcbio.com ↗
Research Third Arc Bio

Tracking coverage

Some source history is available; coverage remains limited.

Momentum +1 · Limited coverage
The latest public index does not report a rank for this company.Index checked:
Fundraising +2 · Awaiting data
No verified dated source evidence recorded.
New VC +3 · Awaiting data
No verified dated source evidence recorded.
Completed exit +10 · Awaiting data
Exit news coverage has not started.

Coverage describes public evidence. Points require a qualifying milestone after your pick.

RiseFinder summary

Third Arc Bio develops antibody technology for oncology and autoimmune conditions.

Visit thirdarcbio.com ↗
Source category

Bio + Health

Category source ↗

Checked

Tracked VC backing

A portfolio listing documents backing; its observation date is not an investment date.

Dated public activity

No dated funding or investment events recorded yet.

History is research context. Only qualifying milestones after your pick earn points.

Company and sources ↗
How it works

Pick up to 50 companies. Your picks are private to your account.

A new US fundraising disclosure (Form D) earns 2 points. A first investment announced by a tracked VC earns 3. Milestones must occur and be observed after your pick.

Measured growth earns 1 point once: the same RiseFinder composite score rises between dated observations after your pick, using one formula version. Where available, a supported public source metric can also qualify. Lower ranks are better; rising counts are better. A completed, dated IPO or acquisition earns 10 points once.

The composite score measures relative public signals on a 0–100 scale. It is not a company valuation. Coverage varies; companies without qualifying history wait for evidence.

Initial imports, old discoveries, follow-ons from existing backers, amendments, undated events and same-day events earn no points.

Points track verified milestones after your pick. They do not represent investment returns.